Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportIn vitro and In vivo Oncology

177Lu-DPI-4452 & 68Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors

Norbert Wiedemann, Frederic Massiere, Franck Brichory, Inês Borrego, Aileen Hoehne, Frank Osterkamp and Antoine Attinger
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 4048;
Norbert Wiedemann
1Debiopharm International SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederic Massiere
1Debiopharm International SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Franck Brichory
2Debiopharm Int.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Inês Borrego
1Debiopharm International SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aileen Hoehne
33B Pharmaceuticals GmbH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Osterkamp
33B Pharmaceuticals GmbH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoine Attinger
1Debiopharm International SA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

4048

Introduction: Carbonic Anhydrase IX (CAIX) is a transmembrane metalloprotease expressed in many hypoxic tumor types and to a very limited extent in healthy organs. CAIX represents an attractive diagnostic and therapeutic target in hypoxic solid tumors such as Colorectal Cancer (CRC) and clear cell Renal Cell carcinoma (ccRCC) for which an important unmet medical need remains. DPI-4452 is a peptidomimetic targeting CAIX which carries a DOTA cage that can be labelled with several different radionuclides for theranostic purposes. Here we report CAIX expression in CRC and ccRCC human samples and evaluate for the first time therapeutic and diagnostic performance of 177Lu-DPI-4452 and 68Ga-DPI-4452 in vitro and in vivo.

Methods: CAIX protein expression was assessed using a validated immunohistochemistry assay (IHC) with an anti-CAIX antibody (M75) on a panel of 30 ccRCC and 85 CRC tumor specimens.

DPI-4452, natLu-DPI-4452, and natGa-DPI-4452 affinity and kinetic interaction to CAIX was assessed by Surface Plasmon Resonance (SPR).

For in vivo characterization of the 177Lu-DPI-4452 and 68Ga-DPI-4452, CAIX-positive human cancer cell line HT-29 (CRC) or SK-RC-52 (ccRCC) were subcutaneously implanted into immunodeficient mice. Animals with each tumor type were divided into 4 treatment groups of 10 mice each: a) Single administration (day 1) of vehicle b) Single administration (day 1) of 100MBq of 177Lu-DPI-4452 c) Single administration (day 1) of 33MBq of 177Lu-DPI-4452 d) Three administrations (day 1, 8, 15) of 33MBq of 177Lu-DPI-4452. To assess radioactivity uptake (as % of injected dose /gram tissue) in the tumor, kidney, and liver, 3 animals per treatment group were imaged by SPECT 4h after each 177Lu-DPI-4452 administration. In both models, tumor volume and body weight were monitored for 42 days from treatment initiation. To correlate the 68Ga-DPI-4452 signal with the 177Lu-DPI-4452 signal in tumors, a satellite group of animals in each model received one injection of 68Ga-DPI-4452 (for PET imaging 1h later) followed 7 days later by an injection of 177Lu-DPI-4452 (for SPECT imaging 4h later).

Results: IHC results demonstrated high-level CAIX expression (H score ≥ 150) in 83% of ccRCC and 29% of CRC tumor cases tested, confirming the relevance of CAIX as a therapeutic target in these 2 indications.

In vitro, DPI-4452 selectively bound to CAIX with sub-nanomolar affinity and showed slow dissociation kinetics. DPI-4452 labeling with lutetium or gallium did not alter its interaction with the target.

In vivo, 177Lu-DPI-4452 treatments were well tolerated. SPECT imaging of HT-29 and SK-RC-52 xenografted animals at 4h after injection demonstrated rapid and high 177Lu-DPI-4452 tumor uptake in both models. Tumor uptake remained stable over multiple 177Lu-DPI-4452 weekly injections suggesting CAIX expression in tumors was not modulated following repeated 177Lu-DPI-4452 administration. Tumor-to-kidney and tumor-to-liver ratios showed preferential uptake in the tumor (T/K: 1.5 and 7.5 and T/L 60 and 300, for HT-29 and SK-RC-52, respectively). A strong and dose-dependent tumor growth inhibition (maximal T/C<20%) was observed in the 100MBq and the 3x33MBq treatment groups for the HT-29 model and the 100MBq, 3x33MBq, and the 33MBq treatment groups for the SK-RC-52 model. Interestingly, in both models, the dose fractionation (3x33MBq) seemed beneficial in the long run, and in the SK-RC-52 model led to tumor stasis sustained until study end (day 42). 68Ga-DPI-4452 tumor uptake evaluated by PET imaging closely matched the 177Lu-DPI-4452 tumor uptake evaluated by SPECT imaging obtained 1 week later for the same animals, demonstrating the theranostic performance of the 68Ga/177Lu-DPI-4452 pair.

Conclusions: These results demonstrate the promising theranostic potential of DPI-4452 for targeting CAIX-expressing CRC and ccRCC tumors.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
177Lu-DPI-4452 & 68Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
177Lu-DPI-4452 & 68Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors
Norbert Wiedemann, Frederic Massiere, Franck Brichory, Inês Borrego, Aileen Hoehne, Frank Osterkamp, Antoine Attinger
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4048;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
177Lu-DPI-4452 & 68Ga-DPI-4452, a new radiopeptide tandem targeting Carbonic Anhydrase IX displays strong theranostic potential in CRC and ccRCC tumors
Norbert Wiedemann, Frederic Massiere, Franck Brichory, Inês Borrego, Aileen Hoehne, Frank Osterkamp, Antoine Attinger
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 4048;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Mesoporous carbon nanotubes radiolabeled with 99mTc: preparation, surface chemistry and distribution study in HepG2 cells in vitro and healthy mice in vivo
  • Positron Emission Tomography of CD33 positive tumors using 89Zr-lintuzumab
  • Development of Fibroblast Activation Protein Inhibitor-based dimeric radiotracers with Improved Tumor Uptake and Retention
Show more In vitro and In vivo Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire